A cutting-edge immunotherapy that uses patient’s unique tumor genetic profile to create customized mRNA vaccines designed to trigger an immune response against cancer cells. The process begins with whole-exome sequencing of the patient’s tumor and normal DNA to identify unique neoantigens – mutated proteins present only on cancer cells. These neoantigens are then encoded into mRNA molecules, which are encapsulated in lipid nanoparticles for delivery. Once administered, the mRNA instructs the patient’s cells to produce these neoantigens, training the immune system to recognize and destroy cancer cells expressing them. Clinical trials conducted in 2026 for non-small cell lung cancer patients showed a 60% reduction in recurrence rates compared to standard treatment, with 5-year survival rates improving from 45% to 72%. This approach represents a paradigm shift from one-size-fits-all cancer treatment to truly personalized therapy, with ongoing research expanding its application to melanoma, breast, and colorectal cancers.